We report our initial experience with three patients who received heart-lung transplants. The primary immunosuppressive agent used was cyclosporin A, although conventional drugs were also administered. In the first patient, a 45-year-old woman with primary pulmonary hypertension, acute rejection of the transplant was diagnosed 10 and 25 days after surgery but was treated successfully; this patient still had normal exercise tolerance 10 months late. The second patient, a 30-year-old man, underwent transplantation for Eisenmenger's syndrome due to atrial and ventricular septal defects. His graft was not rejected, and his condition was markedly improved eight months after surgery. The third patient, a 29-year-old woman with transposition of the great vessels and associated defects, died four days postoperatively of renal, hepatic, and pulmonary complications. We attribute our success to experience with heart-lung transplantation in primates, to the use of cyclosporin A, and to the anatomic and physiologic advantages of combined heart-lung replacement. We hope that such transplants may ultimately provide an improved outlook for selected terminally ill patients with pulmonary vascular disease and certain other intractable cardiopulmonary disorders.

No abstract

To determine which groups of patients are at highest risk for operative or late mortality, 259 consecutive patients who underwent operation between 1978 and 1984 were studied; 170 underwent aortic valve replacement and 89 underwent aortic valve replacement combined with coronary artery bypass grafting. Multivariate analysis of risk factors selected emergency operation and patient age older than 70 years as the strongest predictors for operative death. Although patients having aortic valve replacement and coronary artery bypass grafting had a higher operative mortality rate (13.5 versus 3.5%), the combined operation had no independent predictive effect on early or late results. At a mean follow-up time of 48 months after surgery, 72% of the survivors of operation were living, 10% were lost to follow-up and 18% were dead. Seventy-seven percent of long-term survivors were in New York Heart Association functional class I or II. The incidence of thromboembolism, paravalvular leak, bacterial endocarditis and hemorrhage each occurred at a rate of less than 1% per patient-year. The factors associated with late death were preoperative age, male sex, left ventricular end-diastolic pressure, cardiac index and functional class. Despite an increase in operative mortality, patients undergoing emergency operation were not at higher risk of late death. Operative mortality is concentrated among several high risk groups. For patients undergoing elective operation, operative mortality is low, especially if the patient is less than 70 years old. Late results are good for all groups of patients undergoing operation, including those who are at greater risk of dying at operation.

A controlled study was undertaken to quantitate and compare the effect of left ventricular bypass (LVB) and left atrial bypass (LAB on left ventricular infarct volume (LVIV). After baseline studies, the left anterior descending coronary artery in each of 30 mongrel dogs was ligated 1-1.5 cm from its origin. After baseline ischemic studies, control dogs (group 1--10 dogs), LAB dogs (group 2--10 dogs), and LVB dogs (group 3--10 dogs) were monitored for four hours. Final infarct size was determined by the nitroblue tetrazolium staining technique. Heart rate, mean arterial pressure, and total systemic flow (TSF) showed no significant difference between control and left heart bypass groups. In group 1, the LVIV was 27.7 +/- 6.5 g/100 g left ventricle (LV). In group 2, left heart bypass (LHB) flow was 90 +/- 4% of TSF. The pressure time index (PTI) was 2845 +/- 52 mm Hg-sec/min. The PTI demonstrated no significant difference from cntrols. In group 2, LVIV was 22.5 +/- 6.0 g/100 g LV. LVIV was reduced 18.8% from controls (p less than 0.08). In group 2, LHB was complete. Left ventricular decompression (group 3) resulted in a PTI of 328 +/- 76 mm Hg-sec/min. The PTI was significantly different (p less than 0.001) from groups 1 and 2. The LVIV was 12.6 +/- 5.1 g/100 g LV. LVIV was reduced 54.5% from controls (p less than 0.001) and 44.0% from group 2 (p less than 0.001). These results suggest that LVB may be useful, not only in supporting the circulation in the patient with myocardial infarct and cardiogenic shock, but also in limiting infarct size.